Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2, Sakaecho, Itabashi-ku, Tokyo, 173-0015, Japan.
Integrated Research Initiative for Living Well With Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Sci Rep. 2023 Jul 27;13(1):12147. doi: 10.1038/s41598-023-39227-x.
Corticobasal syndrome (CBS) is characterized by symptoms related to the asymmetric involvement of the cerebral cortex and basal ganglia. However, early detection of asymmetric imaging abnormalities can be challenging. Previous studies reported asymmetric F-THK5351 PET abnormalities in CBS patients, but the sensitivity for detecting such abnormalities in larger patient samples, including early-stage cases, remains unclear. Patients clinically diagnosed with CBS were recruited. All patients displayed asymmetric symptoms in the cerebral cortex and basal ganglia. Asymmetric THK5351 PET abnormalities were determined through visual assessment. Brain MRI, perfusion SPECT, and dopamine transporter (DAT) SPECT results were retrospectively reviewed. The 15 patients had a median age of 72 years (59-86 years) and a disease duration of 2 years (0.5-7 years). Four patients met the probable and 11 met the possible CBS criteria according to Armstrong criteria at the time of PET examination. All patients, including early-stage cases, exhibited asymmetric tracer uptake contralateral to their symptom-dominant side in the cerebral cortex/subcortical white matter and striatum (100%). The sensitivity for detecting asymmetric imaging abnormalities contralateral to the symptom-dominant side was 86.7% for brain MRI, 81.8% for perfusion SPECT, and 90% for DAT SPECT. White matter volume reduction was observed in the subcortical region of the precentral gyrus with increased THK5351 uptake, occurring significantly more frequently than gray matter volume reduction. THK5351 PET may be a sensitive imaging technique for detecting asymmetric CBS pathologies, including those in early stages.
皮质基底节综合征(CBS)的特征是与大脑皮层和基底节不对称受累相关的症状。然而,早期发现不对称的影像学异常可能具有挑战性。先前的研究报告称 CBS 患者存在不对称的 F-THK5351 PET 异常,但在包括早期病例在内的更大患者样本中,检测到这种异常的敏感性尚不清楚。
我们招募了临床诊断为 CBS 的患者。所有患者均表现出大脑皮层和基底节的不对称症状。通过视觉评估确定不对称的 THK5351 PET 异常。回顾性审查脑 MRI、灌注 SPECT 和多巴胺转运体(DAT)SPECT 结果。15 名患者的中位年龄为 72 岁(59-86 岁),病程为 2 年(0.5-7 年)。根据 PET 检查时的 Armstrong 标准,4 名患者符合可能和 11 名患者符合可能 CBS 标准。所有患者,包括早期病例,均表现出与症状优势侧相对的大脑皮层/皮质下白质和纹状体(100%)对侧摄取剂不对称。与症状优势侧相对的不对称影像学异常的检测敏感性,脑 MRI 为 86.7%,灌注 SPECT 为 81.8%,DAT SPECT 为 90%。在 THK5351 摄取增加的中央前回皮质下区域观察到白质体积减少,比灰质体积减少更频繁。THK5351 PET 可能是一种敏感的影像学技术,用于检测不对称的 CBS 病理学,包括早期阶段。